Avava, a medical aesthetics platform company, secures $35million in funding. The round consisted of $25M in proceeds from new and existing investors including its strategic partner, Jeisys Medical, Inc, and $10M in growth capital from Catalio Capital Management.
With the help of its patented Focal Point TechnologyTM, the company plans to use the funds to expedite the commercialization of its flagship product, MIRIA, a new class of aesthetic dermatology lasers that improves skin revitalization results for patients of all skin tones by precisely delivering energy to any location on the skin.
Read also – [Funding News] MA-based Posh AI Secures Strategic Funding
Under the direction of CEO Dr. Irina Erenburg, it is providing a novel class of customisable intradermal lasers. Through the use of patented and exclusive Focal Point TechnologyTM, which maps out a customised skin care regimen and is guided by sophisticated skin imaging, laser energy is precisely supplied at the therapeutic depth that produces the best results for all skin types and tones.
About AVAVA
AVAVA™ developed a new class of FDA-cleared, non-invasive aesthetic medical devices with patented precision technology to provide best in class patient and provider experience for all skin tones.
The AVAVA proprietary Focal Point Technology™ is complemented by AVAVASite, a high-resolution interactive imaging system, which provides treatment intelligence to map and guide real-time therapy with actionable data, to unlock safe and effective treatments.
